Inhaled Dry Powder of Antiviral Agents: A Promising Approach to Treating Respiratory Viral Pathogens

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2025 Feb 26

PMID 40007007

Authors

Tushar Saha

Zia Uddin Masum

Anik Biswas

Moushumi Afroza Mou

Sohag Ahmed

Tamal Saha

Affiliations

Soon will be listed here.

Abstract

Inhaled dry powder formulations of antiviral agents represent a novel and potentially transformative approach to managing respiratory viral infections. Traditional antiviral therapies in the form of tablets or capsules often face limitations in terms of therapeutic activity, systemic side effects, and delayed onset of action. Dry powder inhalers (DPIs) provide a targeted delivery system, ensuring the direct administration of antivirals to the infection site, the respiratory tract, which potentially enhance therapeutic efficacy and minimize systemic exposure. This review explores the current state of inhaled dry powder antiviral agents, their advantages over traditional routes, and specific formulations under development. We discuss the benefits of targeted delivery, such as improved drug deposition in the lungs and reduced side effects, alongside considerations related to the formulation preparation. In addition, we summarize the developed (published and marketed) inhaled dry powders of antiviral agents.

References

Vermillion M, Murakami E, Ma B, Pitts J, Tomkinson A, Rautiola D . Inhaled remdesivir reduces viral burden in a nonhuman primate model of SARS-CoV-2 infection. Sci Transl Med. 2021; 14(633):eabl8282. PMC: 8961622. DOI: 10.1126/scitranslmed.abl8282. View

Gaikwad S, Pathare S, More M, Waykhinde N, Laddha U, Salunkhe K . Dry Powder Inhaler with the technical and practical obstacles, and forthcoming platform strategies. J Control Release. 2023; 355:292-311. DOI: 10.1016/j.jconrel.2023.01.083. View

Ari A . Practical strategies for a safe and effective delivery of aerosolized medications to patients with COVID-19. Respir Med. 2020; 167:105987. PMC: 7172670. DOI: 10.1016/j.rmed.2020.105987. View

Borghardt J, Kloft C, Sharma A . Inhaled Therapy in Respiratory Disease: The Complex Interplay of Pulmonary Kinetic Processes. Can Respir J. 2018; 2018:2732017. PMC: 6029458. DOI: 10.1155/2018/2732017. View

Young P, Price R, Tobyn M, Buttrum M, Dey F . Effect of humidity on aerosolization of micronized drugs. Drug Dev Ind Pharm. 2003; 29(9):959-66. DOI: 10.1081/ddc-120025453. View

Ghosh S, Dellibovi-Ragheb T, Kerviel A, Pak E, Qiu Q, Fisher M . β-Coronaviruses Use Lysosomes for Egress Instead of the Biosynthetic Secretory Pathway. Cell. 2020; 183(6):1520-1535.e14. PMC: 7590812. DOI: 10.1016/j.cell.2020.10.039. View

Lynch 3rd J, Fishbein M, Echavarria M . Adenovirus. Semin Respir Crit Care Med. 2011; 32(4):494-511. DOI: 10.1055/s-0031-1283287. View

Ong C, Migliori G, Raviglione M, Macgregor-Skinner G, Sotgiu G, Alffenaar J . Epidemic and pandemic viral infections: impact on tuberculosis and the lung: A consensus by the World Association for Infectious Diseases and Immunological Disorders (WAidid), Global Tuberculosis Network (GTN), and members of the European Society of.... Eur Respir J. 2020; 56(4). PMC: 7527651. DOI: 10.1183/13993003.01727-2020. View

Wagoner J, Herring S, Hsiang T, Ianevski A, Biering S, Xu S . Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2. Microbiol Spectr. 2022; 10(5):e0333122. PMC: 9718484. DOI: 10.1128/spectrum.03331-22. View

10.

Hassan M, Lau R . Effect of particle shape on dry particle inhalation: study of flowability, aerosolization, and deposition properties. AAPS PharmSciTech. 2009; 10(4):1252-62. PMC: 2799579. DOI: 10.1208/s12249-009-9313-3. View

11.

Molimard M, Raherison C, Lignot S, Depont F, Abouelfath A, Moore N . Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J Aerosol Med. 2003; 16(3):249-54. DOI: 10.1089/089426803769017613. View

12.

Shetty N, Cipolla D, Park H, Zhou Q . Physical stability of dry powder inhaler formulations. Expert Opin Drug Deliv. 2019; 17(1):77-96. PMC: 6981243. DOI: 10.1080/17425247.2020.1702643. View

13.

Mitra R, Baviskar P, Duncan-Decocq R, Patel D, Oomens A . The human respiratory syncytial virus matrix protein is required for maturation of viral filaments. J Virol. 2012; 86(8):4432-43. PMC: 3318654. DOI: 10.1128/JVI.06744-11. View

14.

Niven R . Prospects and challenges: inhalation delivery systems. Ther Deliv. 2013; 4(5):519-22. DOI: 10.4155/tde.13.18. View

15.

Ganjian H, Zietz C, Mechtcheriakova D, Blaas D, Fuchs R . ICAM-1 Binding Rhinoviruses Enter HeLa Cells via Multiple Pathways and Travel to Distinct Intracellular Compartments for Uncoating. Viruses. 2017; 9(4). PMC: 5408674. DOI: 10.3390/v9040068. View

16.

Carstens E . Ratification vote on taxonomic proposals to the International Committee on Taxonomy of Viruses (2009). Arch Virol. 2009; 155(1):133-46. PMC: 7086975. DOI: 10.1007/s00705-009-0547-x. View

17.

Greber U . Adenoviruses - Infection, pathogenesis and therapy. FEBS Lett. 2020; 594(12):1818-1827. DOI: 10.1002/1873-3468.13849. View

18.

Peltola V, Waris M, Osterback R, Susi P, Hyypia T, Ruuskanen O . Clinical effects of rhinovirus infections. J Clin Virol. 2008; 43(4):411-4. DOI: 10.1016/j.jcv.2008.08.014. View

19.

Feikin D, Higdon M, Abu-Raddad L, Andrews N, Araos R, Goldberg Y . Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression. Lancet. 2022; 399(10328):924-944. PMC: 8863502. DOI: 10.1016/S0140-6736(22)00152-0. View

20.

Seow H, Liao Q, Lau A, Leung S, Yuan S, Lam J . Dual targeting powder formulation of antiviral agent for customizable nasal and lung deposition profile through single intranasal administration. Int J Pharm. 2022; 619:121704. PMC: 8958263. DOI: 10.1016/j.ijpharm.2022.121704. View